Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in crystal-induced inflammation pathogenesis and management.

Frédéric Lioté1, Hang-Korng Ea

  • 1Fédération de Rhumatologie (pôle appareil locomoteur), INSERM U606, Paris 7 Medical University, centre Viggo Petersen (Assistance Publique- Hôpitaux de Paris), hôpital Lariboisière, 2, rue Ambroise Paré, 75010 PARIS, France. frederic.liote@lrb.aphp.fr

Current Rheumatology Reports
|May 29, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update.

Joint bone spine·2026
Same author

Urate Lowering and Cardiovascular Risk-Extending the Benefits of a Treat-to-Target Strategy in Gout.

JAMA internal medicine·2026
Same author

Intra-articular sustained-release colchicine is efficacious in an inflammatory arthritis rat model.

RMD open·2025
Same author

Methotrexate osteopathy in rheumatoid arthritis.

Joint bone spine·2025
Same author

Exploring Patients' Profiles Associated With the Resolution of Acute Calcium Pyrophosphate Arthritis Treated With Colchicine and Prednisone: Post Hoc Analysis of a Randomized Controlled Trial.

Arthritis care & research·2025
Same author

Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial.

The Lancet. Rheumatology·2025

Crystal-induced inflammation involves innate immunity and inflammasome activation. Gout management guidelines and treatments for calcium pyrophosphate dihydrate crystal inflammation are reviewed.

Area of Science:

  • Rheumatology and immunology
  • Crystal-induced inflammation pathogenesis

Background:

  • Crystal-induced inflammation involves monosodium urate, calcium pyrophosphate dihydrate, and basic calcium phosphate crystals.
  • Innate immunity and inflammasome activation are key early pathogenic events.
  • Inflammasome activation leads to interleukin-1 processing and secretion, influencing cellular responses.

Purpose of the Study:

  • To review the management of acute and chronic monosodium urate crystal-induced inflammation (gout).
  • To report evidence-based recommendations for gout management.
  • To discuss potential anti-inflammatory agents for calcium pyrophosphate dihydrate crystal inflammation.

Main Methods:

  • Critical review of gout management by a European working group.
  • Development of 12 evidence-based recommendations on behalf of the European League against Rheumatism.

Related Experiment Videos

  • Literature review on treatments for calcium pyrophosphate dihydrate crystal inflammation.

    • Main Results:

    • 12 evidence-based recommendations for gout management have been reported.
    • Colchicine and methotrexate show potential as anti-inflammatory agents for calcium pyrophosphate dihydrate crystal inflammation.

    Conclusions:

    • Crystal-induced inflammation pathogenesis is evolving with new insights into innate immunity and inflammasome pathways.
    • Established guidelines and evidence-based recommendations exist for gout management.
    • Colchicine and methotrexate are potential therapeutic options for calcium pyrophosphate dihydrate crystal inflammation.